Regenxbio Inc. to acquire Dimension Therapeutics Inc. and with it DTX 201, DTX 301 and DTX 401.

Regenxbio Inc. and Dimension Therapeutics, Inc. announced that they have entered into a definitive agreement under which Regenxbio will acquire Dimension in an all-stock transaction for an implied value of approximately $3.41 per share. The boards of directors of both companies have unanimously approved the transaction. Upon completion of the acquisition, Regenxbio will add two lead product candidates to its pipeline: DTX 301 for the treatment of ornithine transcarbamylase (OTC) deficiency, which is designed to use the NAV AAV8 vector to deliver a copy of the OTC gene to liver cells. DTX 301 is being evaluated under an active investigational new drug (IND) application for a Phase I/II clinical trial; and DTX 401 for the treatment of glycogen storage disease type Ia (GSDIa), which is designed to use the NAV AAV8 vector to deliver a copy of the glucose-6-phosphatase (G6Pase) gene to liver cells. An IND application is anticipated to be filed for DTX 401 in early 2018. Both DTX 301 and DTX 401 have been granted Orphan Drug Designation in the United States and Europe. In addition, Regenxbio will acquire DTX 201 for the treatment of hemophilia A. DTX 201 is designed to use Regenxbio�s NAV Technology to deliver a copy of the Factor VIII gene to liver cells, and is partnered through a global development and commercialization collaboration with Bayer. An IND application is anticipated to be filed for DTX 201 in early 2018.